Cassie Allan is the Lead Pharmacist for Correctional Primary Health Services in Tasmania, where she leads a team responsible for the statewide pharmacy service supporting the Tasmanian Prison Service, Tasmania’s youth detention centre, and the state’s forensic psychiatric facility.
Cassie has worked in the correctional health sector for the past 10 years, developing extensive experience in delivering pharmacy services across complex and specialised healthcare environments. Her role encompasses clinical pharmacy practice, leadership, and the coordination of pharmacy services across multiple correctional and forensic settings.
Prior to specialising in correctional health, Cassie worked in community pharmacy and provided Home Medicines Reviews (HMRs) and Residential Medication Management Reviews (RMMRs) through Consultant Pharmacy Services.
Cassie has also contributed to the broader pharmacy profession through her work with the Pharmaceutical Society of Australia (PSA), initially as a member of the Branch Committee and subsequently as a Programs Pharmacist. In this role, she supported pharmacists through practice support and professional advocacy, delivered intern pharmacist and pharmacy technician training, and contributed to continuing professional development initiatives.
Her professional interests include pharmacy practice in complex healthcare settings, medication management, workforce development, and improving the delivery of pharmacy services to vulnerable and diverse patient populations.
Avi is the Opioid Substitution Treatment and Addiction Medicine pharmacist at the Woodford Correctional Centre. He has experience across hospital and correctional healthcare settings in both rural and metropolitan areas. His professional interests include improving the outcomes for incarcerated individuals with complex healthcare needs and supporting their reintegration into the community. He is committed to advancing the role of pharmacists in correctional healthcare and Alcohol and Other Drugs services by promoting innovative patient-centred models of care.
Tanya Burgess is the Coordinator Pharmacist for the Western Australian Voluntary Assisted Dying (VAD) Statewide Pharmacy Service, where she provides leadership and oversight of pharmacy services supporting VAD practice across Western Australia. In this role, she works closely with practitioners, health services, policymakers and multidisciplinary stakeholders to ensure safe, consistent and patient-centred access to VAD medicines and pharmacy support.
Tanya has extensive experience in hospital pharmacy and previously worked as a Clinical Pharmacist at Fremantle Hospital, where she developed broad expertise in patient care, medication management and multidisciplinary collaboration. Her clinical background provides a strong foundation for navigating the complex clinical, operational and governance challenges associated with VAD service delivery.
With a particular interest in service development, workforce sustainability and quality improvement, Tanya has contributed to the establishment and ongoing evolution of VAD pharmacy services in Western Australia. She is also involved in research and evaluation activities aimed at improving understanding of the practitioner experience, service delivery models and patient outcomes within VAD practice.
Tanya is passionate about delivering compassionate, person-centred care and supporting healthcare professionals to provide safe and effective end-of-life care in an evolving healthcare landscape.
Michael has over 30 years’ experience in clinical medicine (infectious diseases & paediatrics) and clinical laboratory microbiology with a particular interest in the epidemiology of vaccine preventable diseases and the diagnosis of infectious diseases in hospital, public health and industry settings. He recently took up the inaugural Director of Research at The Prince Charles Hospital in Brisbane.
He is a past Principal Medical Officer and Director of CoVID-19 Pharmacovigilance at the Therapeutic Goods Administration, Department of Health & Ageing, Australian Government (2021-2022), Director of Scientific Affairs & Public Health for GSK Vaccines in the Greater China Intercontinental region based in Singapore (2014-2020) and Director of Infectious Diseases at the Royal Children’s Hospital-Brisbane and a practising Clinical Microbiologist at the Royal Brisbane & Women’s Hospitals (2000-2014). Michael is a past full member of the Australian Technical Advisory Group for Immunisation from 2007 to 2013.
Karen has a significant background in pharmacy education and training. She has worked as an Associate Lecturer for the University of Queensland and Queensland University of Technology, and as an Education and Training Coordinator within a Queensland Health Pharmacy Practice Development Unit. She contributed to the early development and implementation of pharmacy workplace-based assessment tools such as the General Level Framework and ClinCAT, and designed and delivered workshops to support pharmacy practitioner development.
Karen has consulted on projects for the Australian Pharmacy Council including Advanced and Extended Pharmacy Practice and the Intern Year Blueprint. She has conducted research in allied health prescribing, taught on prescribing training programs, and worked with the Office of the Chief Allied Health Officer to deliver transition of care and collaborative pharmacist medication prescribing projects.
Since 2024, she has been working as the Queensland Health Statewide Pharmacy Clinical Education and Training Program Manager and has been instrumental in strengthening collaboration with education providers. Through the Queensland Health Pharmacy Education Collaborative, she is currently leading initiatives to support workforce readiness and facilitate the transition to the new Doctor of Pharmacy programs.
Emma Whitney is an Infectious Disease (ID) / Antimicrobial Stewardship (AMS) Pharmacist at The Canberra Hospital and an ID/AMS Advanced Training Resident Pharmacist. She has more than five years' experience across a range of clinical specialties at The Canberra Hospital and completed the AdPha Resident Training Program in 2023.
Prudence is the Pharmacist Team Leader of the Metro North Kidney Health Service. She has experience in Vasculitis, General Nephrology, Haemodialysis, Peritoneal dialysis, Home therapies, Kidney Supportive Care and Transplant clinics. She enjoys working in kidney health as it is a very collaborative specialty with complex patients.
Professor Mitra is a full-time Emergency Physician, director of emergency medicine research at the Alfred Care Group, and head of the Emergency Research Unit at the School of Public Health and Preventive Medicine, Monash University. Prof Mitra is a member of the clinical research and ethics committee for Australian Red Cross Lifeblood. He oversees an active research program focused on the resuscitation of patients with critical bleeding.
Dominic is a pharmacist and health informaticist currently leading the AI Medical Scribe implementation at Gold Coast Hospital and Health Service (GCHHS) and the Office of the Chief Allied Health Officer (OCAHO) AI Scribe Implementation Support Project. Dominic brings practical insights from the front line of AI implementation, including the challenges, opportunities and considerations involved in introducing AI Medical scribes into clinical practice. Prior to his role in Digital Health and Innovation, Dominic’s career began as a community pharmacist in regional Far North Queensland before becoming a clinical pharmacist at Gold Coast University Hospital. His professional interests are palliative care, health analytics, and digital optimisation.
Tim is a clinical academic pharmacist from Brisbane, Australia. He is the team leader of mental health pharmacy at the Princess Alexandra Hospital, and at the University of Queensland teaches evidence based medicine and quality use of medicines into the Bachelor of Pharmacy and the Master of Clinical Pharmacy programmes. His research interests include psychopharmacology, treatment-resistant schizophrenia and the safe use of antipsychotic medicines, particularly clozapine and cardiac safety.